login
Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

FDA grants priority review for rivaroxaban supplemental new drug application for the treatment DVT and PE


Tuesday, 10 Jul 2012 12:58

The US Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental new drug applications (sNDAs) filed on 2 May 2012 for rivaroxaban  (Xarelto, Bayer/Janssen), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis(DVT), pulmonary embolism (PE), and to prevent recurrent deep vein thrombosis and pulmonary embolism. 


The FDA grants priority review to medicines that offer major advances in care or provide a treatment where no adequate therapy exists. Under the prescription drug user fee act (PDUFA), FDA will aim to complete its review within six months from the receipt of the sNDA submission, rather than the standard 10 month review cycle.

“We are delighted to have received a priority review designation for Xarelto for the treatment of pulmonary embolism and deep vein thrombosis, and also to prevent the recurrence of these conditions. Each year an estimated 900,000 Americans experience a DVT or PE, and one third of those events are fatal. If approved for these indications, Xarelto has the potential to address critical unmet needs in treating patients with these serious medical conditions,” said Paul Burton, vice president, Cardiovascular Franchise Medical Leader, Janssen R&D.


The submissions are supported by data from the global EINSTEIN programme, which includes two phase 3 studies evaluating the safety and efficacy of rivaroxaban in the treatment of patients with acute symptomatic DVT or PE and the prevention of recurrent events in these patients. A third phase 3 study evaluated the safety and efficacy of rivaroxaban in the long-term prevention of recurrent DVT and PE. In total, these phase 3 studies included more than 9,400 patients.


Separately, Janssen R&D announced it is withdrawing the sNDA for the use of rivaroxaban to reduce the risk of stent thrombosis in patients with acute coronary syndrome (ACS). The company is withdrawing this sNDA because it is contingent on a separate sNDA, for rivaroxaban to reduce of the risk of secondary cardiovascular events in patients with ACS, which Janssen R&D received a complete response letter from the FDA on 21 June 2012. Data from the ATLAS ACS 2 TIMI 51 trial support both sNDAs.


“We remain confident in the overall study results from the ATLAS ACS 2 TIMI 51 trial, including the observed reduction in stent thrombosis that formed the basis for this separate sNDA,” said Burton. “Our top priority is to work with FDA on our original sNDA for ACS and submit our reply to the complete response letter as soon as possible. We plan to resubmit the sNDA for stent thrombosis at the same time.”




Add New Comment

Related Items


Most popular


Philips and Academic Medical Center aim to improve care for diabetic patients with severe foot complications
Thursday, 28 May 2015
The European study in which Philips and AMC are collaborating will start in the summer of 2015 with final results expected in 2017. Philips and Academic Medical Center aim to improve care for diabetic patients with severe foot complications

FDA grants premarket approval for Enroute transcarotid stent system
Tuesday, 19 May 2015
The Enroute transcarotid stent (Silk Road Medical) is the first carotid stent that is introduced and implanted into the carotid artery through a direct common carotid access point to enable a safe ... FDA grants premarket approval for Enroute transcarotid stent system

Companies announce new round of renal denervation randomised trials
Monday, 08 Jun 2015
Medtronic has announced the initiation of the SPYRAL HTN clinical trial programme studying renal denervation in uncontrolled hypertension, and Boston Scientific has announced the initiation of the RED... Companies announce new round of renal denervation randomised trials

Features


Aneurysm Coiling Efficiency (ACE) registry shows positive results for Ruby coil peripheral vasculature
Wednesday, 10 Jun 2015
The Aneurysm Coiling Efficiency registry offers an opportunity to study the demographics and long-term outcomes of a cohort of patients with embolization of the peripheral vasculature using Ruby ... Aneurysm Coiling Efficiency (ACE) registry shows positive results for Ruby coil peripheral vasculature

Interventional radiology solutions for hydatic disease
Wednesday, 10 Jun 2015
Hydatid disease (cystic Echinococcus) caused by Echinococcus granulosus is an endemic disease and a significant public health problem in many parts of the world. Interventional radiology solutions for hydatic disease

Profiles


Lindsay Machan
Thursday, 28 May 2015
“Focussing on maximising rewards has sidelined more ideas than it has helped individual inventors. S... Lindsay Machan

Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions